US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
DX

DXCM

$83.65
Tracked investors holding DXCM
InvestorFirmPositionWeightAs of
Ray Dalio Bridgewater Associates $27M 0.1% 2026-06-30
Ken Fisher Fisher Asset Management $4M 0.0% 2026-06-30
Azzad Asset Management Azzad Asset Management $1M 0.1% 2026-06-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-08-06
🕌 Held by MNZL HTR non-permissible income 0.07%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
🔴 AVOID
The main driver: lagging the market by 6.6%, insider selling on the open market. Too many signals pointing the wrong...
41
of 100
Setup confidence — system conviction, not win probabilityD
Why this signal?
Structure2 of 5 timeframes bullish · 87.0% aligned
VWAPPrice below VWAP ($85.07)
VolumeRelative volume 3.2× the 20-day average
Momentum10-day rate of change -6.5%
Overall readAVOID

Dexcom Inc (DXCM) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.

Market & analysts
Wall Street consensus
BUY
36 analysts
Institutional own.
106.6% *
of shares
Momentum (10d)
-6.5%
rate of change
SMC grade
D · 41
87.0% aligned
COMPLIANT
Sharia compliance
🕌 MNZL
Held by real halal ETF(s)
0.07%
Non-permissible income — HTR, from filings (2025-12-31)
D · 41
SMC grade — 87.0% timeframe alignment
-6.5%
Rate of change (10d)
BUY
Wall Street consensus (36)
106.6%
Institutional ownership *

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for DXCM — this runs off the critical path so the page paints first. It will appear here on its own.

92.3482.9673.5964.2154.842025-09-112026-03-132026-09-11

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
80.40
S2
81.34
S1
82.93
PIVOT
83.87
R1
85.46
R2
86.40
R3
87.99

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
84.2746 96.6454
±6.84% from 90.46, made 2026-09-02 · resolves 2026-09-09
STRONG BUY
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 22051 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

NEUTRAL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesNEUTRAL
6 buy · 0 neutral · 6 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)41.80NEUTRAL
Stochastic %K (14)13.01BUY
CCI (20)-159.76BUY
Williams %R (14)-86.99BUY
MACD (12,26,9)-1.31SELL
ROC (10)-6.34SELL
Momentum (10)-5.66SELL
EMA (10)86.51SELL
SMA (10)87.59SELL
EMA (20)86.91SELL
SMA (20)88.74SELL
EMA (30)85.88SELL
SMA (30)88.08SELL
EMA (50)83.15BUY
SMA (50)82.43BUY
EMA (100)78.13BUY
SMA (100)74.97BUY
EMA (200)73.56BUY
SMA (200)71.39BUY

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About Dexcom Inc

Healthcare · Medical Devices

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

dexcom.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Verdict

🔴 AVOID

The main driver: lagging the market by 6.6%, insider selling on the open market. Too many signals pointing the wrong way. Wait for the picture to improve before committing capital.

Scores: 1 bullish / 3 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

TimeframeBiasBars
📅 Daily BEARISH 62
⏰ 4H BEARISH 38
🕐 1H BEARISH 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

0.72
MACD (no fresh cross)
$84.85
Volume POC (today)
$84.27 – $85.66
Value area

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

CLUSTER SELL   0 buys · 13 sells

Recent: SAYER KEVIN R sold 309662 sh @ $89.71 (2026-08-20); SAYER KEVIN R sold 302214 sh @ $91.41 (2026-08-20); SAYER KEVIN R sold 302311 sh @ $90.78 (2026-08-20)

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-01 · Asset managers net 934180 (-19048)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.